|2003||Saudi Arabia||Hospital outbreak from contaminated nebulized salbutamol|||
|2003||US||Contaminated over-the-counter nasal spray|||
|2004||US||Hospital outbreak from prefabricated moist washcloths|||
|2007||Taiwan|| Hospital outbreak from contaminated heparin
|2008||Germany||Hospital outbreak from prefabricated moist washcloths|||
|2010||Japan|| Neonatal intensive care unit
|2012||India||Pediatric intensive care unit and pediatric ward of tertiary care hospital|||
|2015||China||Surgical intensive care unit from contaminated ventilators|||
|2016||US||Pediatric hospital outbreak from contaminated liquid docusate|||
|2017||Australia||Contaminated ultrasound gel used for central line insertion|||
||Hospital outbreak from contaminated octenidine mouthwash solution|||
In addition to the threat among immunocompromised patients in general, Bcc is an opportunistic pathogen that is particularly dangerous for people with CF. It causes severe decline in lung function, leading to a potentially life-threatening systemic infection known as cepacian syndrome. Cepacian syndrome is characterized by necrotizing pneumonia and bacteremia.
The resistance to antibiotics of Burkholderia cepacia complex poses danger for cystic fibrosis patients
Bcc is typically resistant to antibiotics and has numerous virulent genetic determinants which make it extremely difficult to treat. An essential component of improved management and prevention of infections is gaining a better understanding of its resistant nature.
Infections with SA and PA are more prevalent than infections with Bcc among CF patients. However, although Bcc infections are less common than other microbiology infections, they are still dangerous and present serious challenges.
Figure 1 demonstrates the prevalence of SA, PA, and Bcc infections among CF patients in the US in 2016.
Figure 1. Prevalence of Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia complex among cystic fibrosis patients in the US, 2016
Source: Cystic Fibrosis Foundation, 2018
Figure 2 demonstrates the prevalence of chronic SA, PA, and Bcc infections among CF patients in Europe in 2016.
Figure 2. Prevalence of chronic infections of Staphylococcus aureus, Pseudomonas aeruginosa, and Burkholderia cepacia complex among cystic fibrosis patients in Europe, 2016
Note: S. aureus data were not available for France.
Source: European Cystic Fibrosis Society, 2019
Lack of research, eradication plan, and standard treatment strategy, as well as in vivo and in vitro testing conflicts, are unmet needs regarding Burkholderia cepacia complex infections among cystic fibrosis patients
As of March 2019, there are no relevant studies of treatments that could eliminate Bcc from the respiratory tract of CF patients. This emphasizes the immediate need for more research into treatment of chronic infections of Bcc among CF patients.
Use of trimethoprim-sulfamethoxazole is generally recommended for treatment of Bcc infections, although no standard treatment strategy exists. If trimethoprim-sulfamethoxazole cannot be administered, then combinations containing first- and second-line agents are considered according to the in vitro antimicrobial susceptibility patterns. Examples of these combinations include ceftazidime, meropenem, and penicillins. As regarding penicillins, different results have been described by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical & Laboratory Standards Institute (CLSI) guidelines. Therefore, in vitro susceptibility assessment is required before administration .
Future considerations to address in order to provide standard treatment or eradication are the following:
• lack of correlation between in vitro and in vivo susceptibility data
• duration of therapy
• use of monotherapy versus combined antibiotic therapy.
 Scoffone, V. C., Chiarelli, L. R., Trespidi, G., Mentasti, M., Riccardi, G., & Buroni, S. (2017). Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches. Frontiers in Microbiology, 8, 1592. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28878751 [Accessed 15 April 2019].
 Memish, Z. A., Stephens, G., Balkhy, H. H., Cunningham, G., Francis, C., & Poff, G. (2009). Outbreak of Burkholderia cepacia bacteremia in immunocompetent children caused by contaminated nebulized sulbutamol in Saudi Arabia. American Journal of Infection Control, 37(5), 431-432. Available from: https://www.ajicjournal.org/article/S0196-6553(06)01192-8/fulltext [Accessed 15 April 2019].
 Centers for Disease Control and Prevention (2004) Notice to Readers: Manufacturer's Recall of Nasal Spray Contaminated with Burkholderia cepacia Complex. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5311a8.htm [Accessed 15 April 2019].
 Centers for Disease Control and Prevention (2004) Notice to Readers: Nosocomial Burkholderia cepacia Infections Associated with Exposure to Sublingual Probes --- Texas, 2004. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5334a7.htm [Accessed 15 April 2019].
 Yang, C. J., Chen, T. C., Liao, L. F., Ma, L., Wang, C. S., Lu, P. L., ... & Huang, M. S. (2008). Nosocomial outbreak of two strains of Burkholderia cepacia caused by contaminated heparin. Journal of Hospital Infection, 69(4), 398-400. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18511156 [Accessed 15 April 2019].
 Martin, M., Christiansen, B., Caspari, G., Hogardt, M., Von Thomsen, A. J., Ott, E., & Mattner, F. (2011). Hospital-wide outbreak of Burkholderia contaminans caused by prefabricated moist washcloths. Journal of Hospital Infection, 77(3), 267-270. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21216034 [Accessed 15 April 2019].
 Kuzumoto, K., Kubota, N., Ishii, K., Yumoto, K., Ogiso, Y., Nakamura, T., ... & Kawakami, Y. (2011). Successful cessation of transmitting healthcare-associated infections due to Burkholderia cepacia complex in a neonatal intensive care unit in a Japanese children's hospital. European Journal of Medical Research, 16(12), 537. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351897/ [Accessed 15 April 2019].
 Mali, S., Dash, L., Gautam, V., Shastri, J., & Kumar, S. (2017). An outbreak of Burkholderia cepacia complex in the paediatric unit of a tertiary care hospital. Indian Journal of Medical Microbiology, 35(2), 216. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28681809 [Accessed 15 April 2019].
 Guo, L., Li, G., Wang, J., Zhao, X., Wang, S., Zhai, L., ... & Cao, B. (2017). Suspicious outbreak of ventilator-associated pneumonia caused by Burkholderia cepacia in a surgical intensive care unit. American Journal of Infection Control, 45(6), 660-666. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28336165 [Accessed 15 April 2019].
 Marquez, L., Jones, K. N., Whaley, E. M., Koy, T. H., Revell, P. A., Taylor, R. S., ... & Campbell, J. R. (2017). An Outbreak of Burkholderia cepacia Complex Infections Associated with Contaminated Liquid Docusate. Infection Control & Hospital Epidemiology, 38(5), 567-573. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28166854 [Accessed 15 April 2019].
 Shaban, R. Z., Maloney, S., Gerrard, J., Collignon, P., Macbeth, D., Cruickshank, M., ... & Wilson, H. L. (2017). Outbreak of health care-associated Burkholderia cenocepacia bacteremia and infection attributed to contaminated sterile gel used for central line insertion under ultrasound guidance and other procedures. American Journal of Infection Control, 45(9), 954-958. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28757084 [Accessed 15 April 2019].
 Becker, S. L., Berger, F. K., Feldner, S. K., Karliova, I., Haber, M., Mellmann, A., ... & Gärtner, B. (2018). Outbreak of Burkholderia cepacia complex infections associated with contaminated octenidine mouthwash solution, Germany, August to September 2018. Eurosurveillance, 23(42). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199865/ [Accessed 15 April 2019].